STAT3 negatively regulates thyroid tumorigenesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 35, 2012, Pages E2361-E2370

  Couto, Joana Pinto ^a,b   Daly, Laura ^c   Almeida, Ana ^a   Knauf, Jeffrey A ^c   Fagin, James A ^c   Sobrinho Simões, Manuel ^a,b,d   Lima, Jorge ^a   Máximo, Valdemar ^a,b   Soares, Paula ^a,b   Lyden, David ^e   Bromberg, Jacqueline F ^c,e  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BINDING PROTEIN; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GLYCOPROTEIN GP 130; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 6; JANUS KINASE; LACTIC ACID; PROTEIN RET; PYRUVATE DEHYDROGENASE KINASE; RAS PROTEIN; SHORT HAIRPIN RNA; STAT3 PROTEIN; TUMOR SUPPRESSOR INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7; UNCLASSIFIED DRUG; BRAF PROTEIN, MOUSE; IL6 PROTEIN, HUMAN; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN RELATED PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-RELATED PROTEIN 1; SOMATOMEDIN BINDING PROTEIN; STAT3 PROTEIN, HUMAN;

AEROBIC GLYCOLYSIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SIZE; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GLUCOSE INTAKE; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THYROID CANCER CELL LINE; THYROID FOLLICULAR CELL; THYROID TUMOR; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; CELL DIVISION; DISEASE MODEL; GENETICS; METABOLISM; METASTASIS; MOUSE; PAPILLARY CARCINOMA; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARCINOMA, PAPILLARY; CELL DIVISION; CELL LINE, TUMOR; CYTOKINE RECEPTOR GP130; DISEASE MODELS, ANIMAL; GENE KNOCKDOWN TECHNIQUES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INTERLEUKIN-6; JANUS KINASES; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MICROENVIRONMENT;

EID: 84871862427     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1201232109     Document Type: Article

References (66)

1. DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Glands (IARC Press, Lyon, France).
2. Fagin JA, Mitsiades N (2008) Molecular pathology of thyroid cancer: Diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 22:955-969.
3. Trovisco V, et al. (2007) Molecular genetics of papillary thyroid carcinoma: Great expectations. Arq Bras Endocrinol Metabol 51:643-653.
4. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA (2008) Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 15:1069-1074.
5. Koperek O, Asari R, Niederle B, Kaserer K (2011) Desmoplastic stromal reaction in papillary thyroid microcarcinoma. Histopathology 58:919-924.
6. Kishimoto T (2005) Interleukin-6: From basic science to medicine-40 years in immunology. Annu Rev Immunol 23:1-21.
7. Taga T, et al. (1989) Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573-581.
8. Hwang JH, et al. (2003) Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: Roles in specific gene regulation and cellular transformation. Mol Endocrinol 17:1155-1166.
9. Mora LB, et al. (2002) Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62:6659-6666.
10. Pedranzini L, Leitch A, Bromberg J (2004) Stat3 is required for the development of skin cancer. J Clin Invest 114:619-622.
11. Berishaj M, et al. (2007) Stat3 is tyrosine-phosphorylated through the interleukin-6/ glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 9:R32.
12. Gao SP, et al. (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117:3846-3856.
13. Sansone P, Bromberg J (2011) Environment, inflammation, and cancer. Curr Opin Genet Dev 21:80-85.
14. de la Iglesia N, et al. (2008) Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 22:449-462.
15. Musteanu M, et al. (2010) Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology 138:1003-1011.
16. Schneller D, et al. (2011) p19(ARF) /p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma. Hepatology 54:164-172.
17. Soares P, et al. (2003) BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578-4580.
18. Hedvat M, et al. (2009) The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16:487-497.
19. Meireles AM, et al. (2007) Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid 17:707-715.
20. Ricarte-Filho JC, et al. (2009) Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69:4885-4893.
21. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE, Jr. (1998) Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 18:2553-2558.
22. Plaza Menacho I, et al. (2005) RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell linederived neurotrophic factor. Cancer Res 65:1729-1737.
23. Schuringa JJ, et al. (2001) MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene 20:5350-5358.
24. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y (2006) The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203:1651-1656.
25. Yang J, et al. (2005) Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 65:939-947.
26. Gough DJ, et al. (2009) Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324:1713-1716.
27. Franco AT, et al. (2011) Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci USA 108:1615-1620.
28. Takeda K, et al. (1998) Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: Generation and characterization of T cell-specific Stat3-deficient mice. J Immunol 161:4652-4660.
29. Wajapeyee N, Kapoor V, Mahalingam M, Green MR (2009) Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. Mol Cancer Ther 8:3009-3014.
30. Suzuki H, et al. (2010) IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis 31:342-349.
31. Vizioli MG, et al. (2010) IGFBP7: An oncosuppressor gene in thyroid carcinogenesis. Oncogene 29:3835-3844.
32. Lin J, et al. (2008) Reactivation of IGFBP7 by DNA demethylation inhibits human colon cancer cell growth in vitro. Cancer Biol Ther 7:1896-1900.
33. Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134: 703-707.
34. Demaria M, Poli V (2011) From the nucleus to the mitochondria and back: The odyssey of a multitask STAT3. Cell Cycle 10:3221-3222.
35. Szczepanek K, Chen Q, Larner AC, Lesnefsky EJ (2012) Cytoprotection by themodulation of mitochondrial electron transport chain: The emerging role of mitochondrial STAT3. Mitochondrion 12:180-189.
36. Yuan Y, Hilliard G, Ferguson T, Millhorn DE (2003) Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem 278:15911-15916.
37. Jung JE, et al. (2008) STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination. Exp Mol Med 40:479-485.
38. Niu G, et al. (2008) Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumorassociated myeloid cells. Mol Cancer Res 6:1099-1105.
39. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL (2003) Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho- Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 9:594-600.
40. Pectasides E, et al. (2010) Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin Cancer Res 16:2427-2434.
41. Kim WG, et al. (2012) Basal STAT3 activities are negatively correlated with tumor size in papillary thyroid carcinomas. J Endocrinol Invest 35:413-418.
42. Zhang J, et al. (2011) Upregulation of the signal transducers and activators of transcription 3 (STAT3) pathway in lymphatic metastases of papillary thyroid cancer. Int J Clin Exp Pathol 4:356-362.
43. Studebaker AW, et al. (2008) Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6- dependent manner. Cancer Res 68:9087-9095.
44. Leslie K, et al. (2010) Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation. Breast Cancer Res 12:R80.
45. Park JI, Strock CJ, Ball DW, Nelkin BD (2003) The Ras/Raf/MEK/extracellular signalregulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol 23:543-554.
46. Borrello MG, et al. (2005) Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 102:14825-14830.
47. Engelmann D, et al. (2009) Transcriptome analysis in mouse tumors induced by Ret- MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance. Endocr Relat Cancer 16:211-224.
48. Puxeddu E, et al. (2005) RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocr Relat Cancer 12:319-334.
49. Grivennikov S, et al. (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103-113.
50. Flowers LO, Subramaniam PS, Johnson HM (2005) A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene 24:2114-2120.
51. Vaccaro A, Chen H, Kunnimalaiyaan M (2006) In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. Anticancer Drugs 17:849-853.
52. Kim EJ, Park JI, Nelkin BD (2005) IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. J Biol Chem 280:4913-4920.
53. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928.
54. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR (2008) Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132:363-374.
55. Hinoue T, et al. (2009) Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One 4:e8357.
56. Wegrzyn J, et al. (2009) Function of mitochondrial Stat3 in cellular respiration. Science 323:793-797.
57. Demaria M, et al. (2010) A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) 2:823-842.
58. Demaria M, et al. (2012) STAT3 can serve as a hit in the process of malignant transformation of primary cells. Cell Death Differ 19:1390-1397.
59. Xu Q, et al. (2005) Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24:5552-5560.
60. Gu Q, Kong Y, Yu ZB, Bai L, Xiao YB (2011) Hypoxia-induced SOCS3 is limiting STAT3 phosphorylation and NF-κB activation in congenital heart disease. Biochimie 93: 909-920.
61. Gao X, Wang H, Yang JJ, Liu X, Liu ZR (2012) Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell 45:598-609.
62. Luo W, et al. (2011) Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxiainducible factor 1. Cell 145:732-744.
63. Ho HH, Ivashkiv LB (2006) Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem 281: 14111-14118.
64. Faustino A, et al. (2012) mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab 97:E1139-E1149.
65. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1:1112-1116.
66. Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24:148-154.